BioNexus Gene Lab secures $500M equity facility from ARC and exclusive VitaGuard MRD license in SE Asia

BioNexus Gene Lab Corp

ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.
BGLC obtains exclusive, perpetual, royalty-free license for VitaGuard MRD liquid biopsy platform in Southeast Asia; $2M fee over 24 months, $500K minimum reagent purchases.
As part of strategic alliance, BGLC issued 392,329 shares to Fidelion (now 16.6% owner) and received 180 Fidelion shares (15% stake).
$500M facility complements $20M ATM program; BGLC retains discretion on draws. ARC prohibited from short-selling or hedging.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.